Quote:

---

on March 27, 2020, when CytoDyn shared results from the first instances of leronlimab treatment on critically ill Covid-19 patients in Intensive Care Units in New York-long before there was any clinical data that might provide a basis on which to question the drug's potential to achieve authorization-an FDA employee commented to colleagues internally "Approval is OUT OF THE QUESTION!!! and "I HATE THEM."

---